AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp

Daliresp is a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease

Press Trust of India May 20, 2019 08:56:45 IST
AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp
  • AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts

  • AstraZeneca requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.

  • Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease

Hyderabad: Pharma major AstraZeneca has filed a petition in a US court, alleging that Aurobindo Pharma is attempting to come out with the generic version of its patented drug Daliresp (Roflumilast Tablet 500 mcg).

In a petition filed in the United States District Court for the District Court of New Jersey on 15 May, AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.

Daliresp isis a prescription medicine used in adults with severe Chronic Obstructive Pulmonary Disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations).

AstraZeneca moves US court against Aurobindo Pharma on generic version of patented drug Daliresp

Representational image. Getty.

AstraZeneca prayed for a permanent injunction, restraining and enjoining Aurobindo Pharma from making, using, selling, offering to sell, or importing any product that infringes the 206, 064, and 142 Patent, including the product (Dalisrep).

AstraZeneca Pharmaceuticals LP is the current holder of New Drug Application for Daliresp (Roflumilast) Tablet 500 mcg, which was first approved by the Food and Drug Administration on 28 February 2011.

Aurobindo Pharma wrote to AstraZeneca Pharmaceuticals LP and AstraZeneca AB on 5 April, 2019 (Notice Letter), saying they had submitted US FDA an Abbreviated New Drug Application (ANDA ) with paragraph IV certifications for the 206, 064, and 142 Patents, the petition said.

Under this, a company can seek FDA approval to market a generic drug before the expiration of patents related to the brand-name drug that the generic seeks to copy.

A city-based pharmaceutical company senior official said patent infringement cases are not uncommon for generic drug makers in USA and the lawsuit would not have any implications on the company's performance.

Updated Date:

also read

Coronavirus Updates: EC moves SC against 'disparaging' remarks by Madras HC on COVID-19 protocol at rallies
India

Coronavirus Updates: EC moves SC against 'disparaging' remarks by Madras HC on COVID-19 protocol at rallies

Coronavirus LIVE Updates: The HC had observed that the EC "should be put on murder charges probably" as political parties flouted COVID-19 protocol in rallies

Coronavirus Updates: First consignments of medical supplies from US expected to reach India by Friday, says report
India

Coronavirus Updates: First consignments of medical supplies from US expected to reach India by Friday, says report

Coronavirus LIVE Updates: An American aircraft carrying medical supplies, including ready-to-use vaccine doses, as well as raw materials for production of COVID-19 vaccines, is expected to land

Coronavirus Updates: Tripura govt sounds alert after cases with three COVID-19 strains are detected
India

Coronavirus Updates: Tripura govt sounds alert after cases with three COVID-19 strains are detected

Coronavirus LIVE Updates: However, Yediyurappa dismissed charges that it was a failure on the part of the government for not getting the vaccine beforehand